Review

mouse obestatin (Echelon Biosciences)

Name: mouse obestatin
Brand: Echelon Biosciences
Rating: 92 (5 reviews)

Echelon Biosciences is a verified supplier

Echelon Biosciences manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Echelon Biosciences mouse obestatin

The thickness of the bar indicates the intensities of the NOEs for the following peptides: (A) human <t>obestatin</t> ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The asterisk (*) represents the C-terminal amidation of the molecule. The dagger (#) represents the differences between human obestatin ( 1 ) and mouse obestatin ( 6 ).

Mouse Obestatin, supplied by Echelon Biosciences, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse obestatin/product/Echelon Biosciences
Average 92 stars, based on 1 article reviews
Price from $9.99 to $1999.99

mouse obestatin - by Bioz Stars, 2025-01

92/100 stars

Images

1) Product Images from "The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin"

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

Journal: PLoS ONE

doi: 10.1371/journal.pone.0045434

The thickness of the bar indicates the intensities of the NOEs for the following peptides: (A) human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The asterisk (*) represents the C-terminal amidation of the molecule. The dagger (#) represents the differences between human obestatin ( 1 ) and mouse obestatin ( 6 ).

Figure Legend Snippet: The thickness of the bar indicates the intensities of the NOEs for the following peptides: (A) human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The asterisk (*) represents the C-terminal amidation of the molecule. The dagger (#) represents the differences between human obestatin ( 1 ) and mouse obestatin ( 6 ).

Techniques Used:

Structural statistics for the ensemble of the best 20 structures of human obestatin (1), its fragments and mouse obestatin (6).

Figure Legend Snippet: Structural statistics for the ensemble of the best 20 structures of human obestatin (1), its fragments and mouse obestatin (6).

Techniques Used:

(A) Human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The Tyr16 side chain is shown in blue.

Figure Legend Snippet: (A) Human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The Tyr16 side chain is shown in blue.

Techniques Used:

(A) Immunocytochemical detection of GPR39 in ARPE-19 cells (objective magnification of 20x). (B) The effect of siRNA depletion of GPR39 on pAkt(S473) and pERK1/2(T202/Y204) in ARPE-19 cells after human obestatin treatment ( 1 , 100 nM, 10 min). The ARPE-19 cells were transfected with GPR39 siRNA prior to obestatin 1 treatment. Equal amounts of protein in each sample were used to assess the expression of GPR39 by western blotting. The GPR39 level was expressed as the fold change relative to the control siRNA-transfected cells (mean ± SE). The protein expression was normalized relative to actin. The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the treated control siRNA group with the control siRNA group; the dagger (#) denotes P <0.05 when comparing the GPR39 siRNA group with the control siRNA group.

Figure Legend Snippet: (A) Immunocytochemical detection of GPR39 in ARPE-19 cells (objective magnification of 20x). (B) The effect of siRNA depletion of GPR39 on pAkt(S473) and pERK1/2(T202/Y204) in ARPE-19 cells after human obestatin treatment ( 1 , 100 nM, 10 min). The ARPE-19 cells were transfected with GPR39 siRNA prior to obestatin 1 treatment. Equal amounts of protein in each sample were used to assess the expression of GPR39 by western blotting. The GPR39 level was expressed as the fold change relative to the control siRNA-transfected cells (mean ± SE). The protein expression was normalized relative to actin. The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the treated control siRNA group with the control siRNA group; the dagger (#) denotes P <0.05 when comparing the GPR39 siRNA group with the control siRNA group.

Techniques Used: Transfection, Expressing, Western Blot

Immunocytochemical analysis of the Ki67 expression in ARPE-19 cells after 24 h of proliferation. A) Control. B) 10% FBS (v/v). C) 100 nM human obestatin ( 1 ). D) 100 nM human non-amidated obestatin ( 2 ). E) 100 nM human (6–23)-obestatin ( 3 ). F) 100 nM human (11–23)-obestatin ( 4 ). G) 100 nM human (16–23)-obestatin ( 5 ). H) 100 nM mouse obestatin ( 6 ). The magnification was 20x. I) Quantification of the immunocytochemical expression of Ki67 in ARPE-19 cells after treatment with 10% FBS (v/v; 100±2), 100 nM human obestatin ( 1 ; 84±1%), 100 nM human non-amidated obestatin ( 2 ; 33±2%), 100 nM human (6–23)-obestatin ( 3 ; 56±3%), 100 nM human (11–23)-obestatin ( 4 ; 67±3%), 100 nM human (16–23)-obestatin ( 5 ; 50±2%) and 100 nM mouse obestatin ( 6 ; 32±2%). The expression of Ki67 was expressed as the fold change relative to the expression level in FBS-treated cells in the positive control (mean ± SE). J) BrdU incorporation in ARPE-19 cells after treatment with 10% FBS (v/v; 100±1), 100 nM human obestatin ( 1 ; 84±4%), 100 nM human non-amidated obestatin ( 2 ; 39±2%), 100 nM human (6–23)-obestatin ( 3 ; 30±1%), 100 nM human (11–23)-obestatin ( 4 ; 52±3%), 100 nM human (16–23)-obestatin ( 5 ; 34±3%) and 100 nM mouse obestatin ( 6 ; 35±1%). The BrdU incorporation was expressed as the fold change relative to the level in FBS-treated cells in the positive control (mean ± SE). The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the peptide-treated ARPE-19 cells groups with the human obestatin ( 1 )-treated group.

Figure Legend Snippet: Immunocytochemical analysis of the Ki67 expression in ARPE-19 cells after 24 h of proliferation. A) Control. B) 10% FBS (v/v). C) 100 nM human obestatin ( 1 ). D) 100 nM human non-amidated obestatin ( 2 ). E) 100 nM human (6–23)-obestatin ( 3 ). F) 100 nM human (11–23)-obestatin ( 4 ). G) 100 nM human (16–23)-obestatin ( 5 ). H) 100 nM mouse obestatin ( 6 ). The magnification was 20x. I) Quantification of the immunocytochemical expression of Ki67 in ARPE-19 cells after treatment with 10% FBS (v/v; 100±2), 100 nM human obestatin ( 1 ; 84±1%), 100 nM human non-amidated obestatin ( 2 ; 33±2%), 100 nM human (6–23)-obestatin ( 3 ; 56±3%), 100 nM human (11–23)-obestatin ( 4 ; 67±3%), 100 nM human (16–23)-obestatin ( 5 ; 50±2%) and 100 nM mouse obestatin ( 6 ; 32±2%). The expression of Ki67 was expressed as the fold change relative to the expression level in FBS-treated cells in the positive control (mean ± SE). J) BrdU incorporation in ARPE-19 cells after treatment with 10% FBS (v/v; 100±1), 100 nM human obestatin ( 1 ; 84±4%), 100 nM human non-amidated obestatin ( 2 ; 39±2%), 100 nM human (6–23)-obestatin ( 3 ; 30±1%), 100 nM human (11–23)-obestatin ( 4 ; 52±3%), 100 nM human (16–23)-obestatin ( 5 ; 34±3%) and 100 nM mouse obestatin ( 6 ; 35±1%). The BrdU incorporation was expressed as the fold change relative to the level in FBS-treated cells in the positive control (mean ± SE). The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the peptide-treated ARPE-19 cells groups with the human obestatin ( 1 )-treated group.

Techniques Used: Expressing, Positive Control, BrdU Incorporation Assay

Image Search Results

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: The thickness of the bar indicates the intensities of the NOEs for the following peptides: (A) human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The asterisk (*) represents the C-terminal amidation of the molecule. The dagger (#) represents the differences between human obestatin ( 1 ) and mouse obestatin ( 6 ).

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques:

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: Structural statistics for the ensemble of the best 20 structures of human obestatin (1), its fragments and mouse obestatin (6).

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques:

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: (A) Human obestatin ( 1 ), (B) human non-amidated obestatin ( 2 ), (C) human (6–23)-obestatin ( 3 ), (D) human (11–23)-obestatin ( 4 ), (E) human (16–23)-obestatin ( 5 ) and (F) mouse obestatin ( 6 ). The Tyr16 side chain is shown in blue.

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques:

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: (A) Immunocytochemical detection of GPR39 in ARPE-19 cells (objective magnification of 20x). (B) The effect of siRNA depletion of GPR39 on pAkt(S473) and pERK1/2(T202/Y204) in ARPE-19 cells after human obestatin treatment ( 1 , 100 nM, 10 min). The ARPE-19 cells were transfected with GPR39 siRNA prior to obestatin 1 treatment. Equal amounts of protein in each sample were used to assess the expression of GPR39 by western blotting. The GPR39 level was expressed as the fold change relative to the control siRNA-transfected cells (mean ± SE). The protein expression was normalized relative to actin. The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the treated control siRNA group with the control siRNA group; the dagger (#) denotes P <0.05 when comparing the GPR39 siRNA group with the control siRNA group.

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques: Transfection, Expressing, Western Blot

Journal: PLoS ONE

Article Title: The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin

doi: 10.1371/journal.pone.0045434

Figure Lengend Snippet: Immunocytochemical analysis of the Ki67 expression in ARPE-19 cells after 24 h of proliferation. A) Control. B) 10% FBS (v/v). C) 100 nM human obestatin ( 1 ). D) 100 nM human non-amidated obestatin ( 2 ). E) 100 nM human (6–23)-obestatin ( 3 ). F) 100 nM human (11–23)-obestatin ( 4 ). G) 100 nM human (16–23)-obestatin ( 5 ). H) 100 nM mouse obestatin ( 6 ). The magnification was 20x. I) Quantification of the immunocytochemical expression of Ki67 in ARPE-19 cells after treatment with 10% FBS (v/v; 100±2), 100 nM human obestatin ( 1 ; 84±1%), 100 nM human non-amidated obestatin ( 2 ; 33±2%), 100 nM human (6–23)-obestatin ( 3 ; 56±3%), 100 nM human (11–23)-obestatin ( 4 ; 67±3%), 100 nM human (16–23)-obestatin ( 5 ; 50±2%) and 100 nM mouse obestatin ( 6 ; 32±2%). The expression of Ki67 was expressed as the fold change relative to the expression level in FBS-treated cells in the positive control (mean ± SE). J) BrdU incorporation in ARPE-19 cells after treatment with 10% FBS (v/v; 100±1), 100 nM human obestatin ( 1 ; 84±4%), 100 nM human non-amidated obestatin ( 2 ; 39±2%), 100 nM human (6–23)-obestatin ( 3 ; 30±1%), 100 nM human (11–23)-obestatin ( 4 ; 52±3%), 100 nM human (16–23)-obestatin ( 5 ; 34±3%) and 100 nM mouse obestatin ( 6 ; 35±1%). The BrdU incorporation was expressed as the fold change relative to the level in FBS-treated cells in the positive control (mean ± SE). The data are expressed as the mean ± SE. The asterisk (*) denotes P <0.05 when comparing the peptide-treated ARPE-19 cells groups with the human obestatin ( 1 )-treated group.

Article Snippet: Human obestatin ( 1 ) and mouse obestatin ( 6 ) were obtained from California Peptide Research Inc. (Napa, CA, US).

Techniques: Expressing, Positive Control, BrdU Incorporation Assay

Review

Structured Review

Images

1) Product Images from "The NMR Structure of Human Obestatin in Membrane-Like Environments: Insights into the Structure-Bioactivity Relationship of Obestatin"

Similar Products

Image Search Results